Dr. Tim Harris is a science and business leader with 45 years of experience guiding and leading R&D.

Most recently, he was Chief Science Advisor to Repertoire Immune Medicines and before that EVP R&D at Bioverativ after being Head of Precision Medicine at Biogen.

Tim started his Biotech career as a scientist at Celltech in the UK in 1981, went to Glaxo group research as Director of Biotechnology in 1989 and came to the USA in 1993 to be VP R&D at Sequana Therapeutics. He was subsequently Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick. He is a Venture Partner at SV Health Sciences Investors.

He founded Caraway Therapeutics, a company therapeutics directed to lysosomal function in 2016 (which was acquired by Merck in 2023) and Catamaran Bio a company developing NK cell therapeutics in 2019.